×

Biotech and Pharmaceuticals Medicine

  • Oct 20- A California judge on Friday threw out a $417 million verdict against Johnson& Johnson in a lawsuit by a woman who claimed she developed ovarian cancer after using its talc-based products like Johnson's Baby Powder for feminine hygiene. The ruling by Los Angeles Superior Court Judge Maren Nelson marked the latest setback facing women and family...

  • Apple has considered an expansion into health care clinics. CNBC explains what this may mean for the company’s future.

  • Drugmaker GlaxoSmithKline said the Food and Drug Administration approved it late Friday. Studies paid for by Glaxo found it prevents shingles in about 90 percent of people. The U.S. Centers for Disease Control and Prevention, though, recommends vaccination for those 60 or older, partly because it loses effectiveness over time.

  • Medical device software updates will become more common practice: Dr. Christian Dameff

    Medcrypt CEO Mike Kijewski and Dr. Christian Dameff, UC San Diego emergency doctor and hacker and security researcher, discuss how to keep your medical devices safe from being hacked.

  • Oct 19- Celgene Corp said on Thursday it would stop two studies of its drug for an inflammatory bowel disease and would not begin a third, following a recommendation by a data monitoring committee. The drug, mongersen, was being tested in late-stage and extension studies as a treatment for Crohn's disease. The company's shares were halted in after-market trading.

  • CHICAGO, Oct 19- Lab experiments on a new strain of the H7N9 bird flu circulating in China suggest the virus can transmit easily among animals and can cause lethal disease, raising alarm that the virus has the potential to trigger a global human pandemic, researchers reported on Thursday. The H7N9 virus has been circulating in China since 2013, causing severe...

  • CHICAGO, Oct 19- Lab experiments on a new strain of the H7N9 bird flu circulating in China suggest the virus can transmit easily among animals and can cause lethal disease, raising alarms that the virus has the potential for triggering a global human pandemic, researchers reported on Thursday. The H7N9 virus has been circulating in China since 2013, causing...

  • LONDON, Oct 19- The World Health Organization's cancer agency dismissed and edited findings from a draft of its review of the weedkiller glyphosate that were at odds with its final conclusion that the chemical probably causes cancer. It issued a report on its assessment of glyphosate- a key ingredient in Monsanto Corp's top-selling weedkiller RoundUp- in...

  • WASHINGTON/ COPENHAGEN, Oct 19- Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration gave the green light to its semaglutide drug. Shares in Novo Nordisk rose almost 3 percent in early trading on Thursday, after the panel late on Wednesday concluded semaglutide is...

  • Oct 18- U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell...

  • Gilead said the price for the therapy with one-time administration would be $373,000. It was approved in August for B-cell acute lymphoblastic leukemia, the most common form of childhood cancer in the United States. "The approval of Yescarta brings this innovative class of CAR-T cell therapies to an additional group of cancer patients with few other options,"...

  • The Food and Drug Administration allowed sales of the treatment from Kite Pharma on Wednesday. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. The treatment, called Yescarta, will cost $373,000 per patient, according to drugmaker Gilead...

  • GILEAD SCIENCES SETS PRICE FOR YESCARTA, CAR-T LYMPHOMA DRUG APPROVED.

  • A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    CNBC's Meg Tirrell reports on the FDA approving Gilead's cancer drug and what its priced at.

  • Oct 18- A new cancer therapy for a type of lymphoma developed by Kite Pharma, which was recently acquired by Gilead Sciences Inc, won U.S. Food and Drug Administration approval on Wednesday, six weeks ahead of schedule. The drug, Yescarta, is the second in a new class of cancer treatments known as chimeric antigen receptor T-cell therapy, or CAR-T, which reprograms the...

  • WASHINGTON, Oct 18- Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Analysts on average expect annual semaglutide sales to reach $3.17 billion by 2023, with...

  • WASHINGTON, Oct 18- Novo Nordisk A/S's new diabetes drug semaglutide is effective, reasonably safe and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA typically follows the recommendations of its advisors. Analysts on average expect annual semaglutide sales to reach $3.17 billion by 2023, with...

  • Oct 18- Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B. The company's shares rose as much as 8 percent but pared gains to trade at $119.98 before the bell. Alnylam said it would...

  • Oct 18- Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B. The company's shares rose as much as 8 percent but pared gains to trade at $119.98 before the bell. Alnylam said it would...

  • Oct 18- U.S. drugmaker Eli Lilly and Co said on Wednesday it will collaborate with CureVac AG on development of up to five immunotherapy cancer vaccines using the German company's messenger RNA technology. Under terms of the deal, CureVac will receive $50 million up front and Lilly will take an equity stake in CureVac worth about $53 million.